New Treatment Boosts Survival in Kids with Neuroblastoma
Cancer is the leading cause of death by disease for children in the United States. Tragically, children with the rare cancer neuroblastoma often succumb to the disease despite aggressive treatment. That is until exciting new research showed that adding an experimental antibody to treatment shows promise to save the lives of children with this…...
Childhood Cancer Treatment by NFCR Partner Receives Fast Track Review and More Good News From the FDA
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, recently announced that the Unites States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to volasertib, one of its drugs. Volasertib is a small molecular inhibitor that has been…...
Pediatric Cancer Facts and the Need for Improved Treatment
September is childhood (or pediatric) cancer awareness month. While all cancers are painful to both the patient, and their loved ones, perhaps no cancer has a more devastating impact on the patient, or his/her family unit, than pediatric cancer. Cancer is the leading cause of death among children under the age…...
Ricardo Garcia: The Power of Repurposing
When volasertib was discontinued after an unsatisfactory Phase III clinical trial as an anti-leukemia drug, it did not die a quick death, or die at all. Like Viagra and thalidomide before it, volasertib was “repurposed;” if the original vision for the compound fails, it is simply a matter of finding…...
Leukemia Drug Finds New Use
Approved by the FDA in 1993, the drug cladribine offered hope for the then-fatal blood cancer called hairy cell leukemia, or HCL, and was soon expanded as a therapy for multiple sclerosis. Developed by NFCR scientist Dr. Dennis Carson at the University of California, San Diego, cladribine acts like a…...